Publications by authors named "J M Chemouny"
Introduction: The objective of this study was to describe kidney involvement in patients with myelodysplastic syndromes (MDS), their treatments, and outcomes.
Methods: We conducted a multicenter retrospective study in seven centers, identifying MDS patients with acute kidney injury (AKI), chronic kidney disease (CKD), and urine abnormalities.
Results: Fifteen patients developed a kidney disease 3 months after MDS diagnosis.
Key Points: A negative change in serum sodium during a dialysis session is an independent factor associated with prolonged dialysis recovery time. Lower hemoglobin is an independent factor associated with fatigue in hemodialysis patients. Hemodiafiltration use in patients age ≥85 years is associated with a longer dialysis recovery time.
View Article and Find Full Text PDFMechanisms underlying the disruption of self-tolerance in acquired autoimmunity remain unclear. Immunoglobulin A (IgA) nephropathy is an acquired autoimmune disease where deglycosylated IgA1 (IgA subclass 1) auto-antigens are recognized by IgG auto-antibodies, forming immune complexes that are deposited in the kidneys, leading to glomerulonephritis. In the intestinal microbiota of patients with IgA nephropathy, there was increased relative abundance of mucin-degrading bacteria, including .
View Article and Find Full Text PDFArticle Synopsis
- Chronic myelomonocytic leukemia (CMML) is a complex blood disorder linked to kidney issues, prompting this study to examine kidney involvement in CMML patients, their treatments, and outcomes.
- In a multicenter retrospective study involving 16 CMML patients with kidney disease, common issues included kidney injury occurring roughly six months post-CMML diagnosis, with significant findings like lysozyme nephropathy and renal infiltration.
- Despite receiving treatment, many patients faced serious kidney complications, and although kidney involvement correlated with higher monocyte counts and treatment eligibility, there was no significant difference in survival rates compared to CMML controls.
Purpose: Therapeutic drug monitoring of tacrolimus using trough concentration (C) is mandatory to ensure drug efficacy and safety in solid organ transplantation. However, C is just a proxy for the area under the curve of drug concentrations (AUC) which is the best pharmacokinetic parameter for exposure evaluation. Some studies suggest that patients may present discrepancies between these two parameters.
View Article and Find Full Text PDF